Biotech stocks are ready to break out. They just need one more thing
Biotech stocks tend to outperform in the months leading up to an interest rate cut. But other factors are driving performance too.
Stay updated with breaking news from Joseph Stringer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biotech stocks tend to outperform in the months leading up to an interest rate cut. But other factors are driving performance too.
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. PHAT, raising the price target to $26 from $23. "PHAT is our top pick…
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),
Operator: Good afternoon. My name is Latif and I will be your conference facilitator.